Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated (LGND) Revenue
Annual & quarterly revenue history · segment & region breakdown
LGND · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsLigand Pharmaceuticals Incorporated trailing twelve-month (TTM) revenue is $0.27B, an increase of 60.40% year-over-year from $0.27B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.27B | +$0.10B | +60.40% |
| 2024-12-31 | $0.17B | +$0.04B | +27.28% |
| 2023-12-31 | $0.13B | -$0.06B | -33.09% |
| 2022-12-31 | $0.20B | -$0.05B | -18.75% |
| 2021-12-31 | $0.24B | +$0.08B | +47.68% |
| 2020-12-31 | $0.16B | +$0.04B | +35.98% |
| 2019-12-31 | $0.12B | -$0.13B | -52.17% |
| 2018-12-31 | $0.25B | +$0.11B | +78.21% |
| 2017-12-31 | $0.14B | +$0.03B | +29.48% |
| 2016-12-31 | $0.11B | +$0.04B | +51.53% |
Compare revenue vs peers
BiotechnologyCompare LGND revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Ligand Pharmaceuticals Incorporated receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Ligand Pharmaceuticals Incorporated reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Ligand Pharmaceuticals Incorporated's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
LGND revenue · 4 questionsLGND's trailing twelve-month (TTM) revenue is $0.27B. That is an increase of 60.40% year-over-year from $0.27B in FY2025.
▸ Source: FMP · Ligand Pharmaceuticals Incorporated SEC filings · GAAP · Ligand Pharmaceuticals Incorporated SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026